# A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants

> **NCT05053165** · PHASE1 · COMPLETED · sponsor: **LISCure Biosciences** · enrollment: 31 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Non-Alcoholic Steatohepatitis

## Interventions

- **DRUG:** LB-P6
- **DRUG:** LB-P8
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05053165
- **Lead sponsor:** LISCure Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-04
- **Primary completion:** 2022-04-01
- **Final completion:** 2022-06-29
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05053165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05053165, "A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05053165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*